SMETANA, Jan, Jan FRÖHLICH, Vladimíra VRANOVÁ, Aneta MIKULÁŠOVÁ, Petr KUGLÍK and Roman HÁJEK. Oligonucleotide-based Array CGH as a Diagnostic Tool in Multiple Myeloma Patients. Klinická onkologie. 2011, vol. 24, Suppl., p. 43-48. ISSN 0862-495X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Oligonucleotide-based Array CGH as a Diagnostic Tool in Multiple Myeloma Patients
Name in Czech Využití techniky komparativní genomové hybridizace na oligonukleotidových čipech jako diagnostického nástroje u pacientů s mnohočetným myelomem
Authors SMETANA, Jan (203 Czech Republic, belonging to the institution), Jan FRÖHLICH (203 Czech Republic), Vladimíra VRANOVÁ (703 Slovakia), Aneta MIKULÁŠOVÁ (203 Czech Republic, belonging to the institution), Petr KUGLÍK (203 Czech Republic) and Roman HÁJEK (203 Czech Republic, guarantor, belonging to the institution).
Edition Klinická onkologie, 2011, 0862-495X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/11:00049842
Organization unit Faculty of Medicine
Keywords in English multiple myeloma; array-CGH; cytogenetics
Tags Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 30/9/2011 12:08.
Abstract
Multiple myeloma (MM) is a hematological disease caused by malignant proliferation of clonal plasma cells (PCs) known for its clinical and biological heterogeneity. Identification of chromosomal changes in genome of PCs plays a key role in MM pathogenesis and is supposed to have important prognostic significance for MM patients. There are two major genetic entities in MM. Hyperdiploid tumors (H-MM), which include about 50% of MM tumors, often have multiple trisomies involving chromosomes 3, 5, 7, 9, 11, 15, 19, and 21 and a substantially lower prevalence of IgH translocations. Nearly half of tumors are non-hyperdiploid (NH-MM), and mostly have one of five recurrent IgH translocations: 11q13 (CCND1), 6p21 (CCND3), 16q23 (MAF), 20q12 (MAFB), and 4p16 (FGFR3 and MMSET). The development and expanded use of new technologies, such as genome-wide array-based comparative genomic hybridization (aCGH) has accelerated genomic research in MM. This technique is a powerful tool to globally analyze recurrent copy number changes in tumor genome in a single reaction and to study cancer biology and clinical behaviors. It widely overcame routinely used cytogenetic techniques (G-banding, FISH) both in minimal resolution of chromosomal changes and amount of obtained genomic data important for further analyses and clinical applications. Array CGH technique is now used to better understanding of molecular phenotypes, sensitivity to particular chemotherapeutic agents, and prognosis of these diseases. This paper brings brief literature and methodic overview of oligonucleotide-based array-CGH technique in MM diagnosis.
Links
GAP304/10/1395, research and development projectName: Analýza klonálních progenitorů plazmatických buněk u monoklonálních gamapatií
Investor: Czech Science Foundation
LC06027, research and development projectName: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NS10207, research and development projectName: Úloha abnormalit chromozómu 1 a kaskády NF-kappaB v patogenezi mnohočetného myelomu
Investor: Ministry of Health of the CR
NS10406, research and development projectName: Vytvoření prognostického panelu u pacientů s monoklonální gamapatií nejasného významu s cílem zabránění transformace v maligní onemocnění.
Investor: Ministry of Health of the CR
PrintDisplayed: 28/4/2024 13:18